本报告描述了由妇科肿瘤学家 (GO) 进行肠道手术的晚期卵巢癌患者的肿瘤学结果，并将结果与​​普通外科医生 (GS) 在最大细胞减灭术期间进行的肠道手术的结果进行了比较。来自六个学术机构的患者患有FIGO III期或IV期卵巢癌并在最大细胞减灭术期间接受过任何肠道手术的患者有资格参加该研究。根据肠道手术是由 GO 还是 GS 进行，将患者分为两组。在两组中，GO 主要参与额外的肠道减灭手术。比较两组的围手术期和生存结果。本研究的 761 例患者中，113 例接受 GO 肠道手术，648 例接受 GS 肠道手术。两组之间在年龄、美国麻醉学会 (ASA) 评分、FIGO 分期、组织学类型、细胞减灭术（初次或间隔减灭手术）时间或并发症方面未观察到明显差异。 GO组的手术时间比GS组短。 Kaplan-Meier 分析显示两组之间没有生存差异。在 Cox 分析中，非浆液性细胞类型和肉眼残留疾病与总体生存率的不利影响相关。然而，GO 进行的肠道手术对生存没有影响。在最大细胞减灭术期间，GO 进行的肠道手术既可行又安全。这些结果应该反映在GO关于肠道手术的培训体系中，并且需要进一步的研究来证实GO在进行宫外手术中可以发挥更大的主导作用。© 2024。外科肿瘤学会。

This report describes the oncologic outcomes for patients with advanced ovarian cancer who had bowel surgery performed by gynecologic oncologists (GOs) and compares the outcomes with those for bowel surgery performed by general surgeons (GSs) during maximal cytoreductive surgery.Patients from six academic institutions who had FIGO stage III or IV ovarian cancer and underwent any bowel surgeries during maximal cytoreductive surgery were eligible for the study. The patients were divided into two groups according to whether bowel surgery was performed by a GO or a GS. In both groups, the GOs were mainly involved in extra bowel debulking procedures. Perioperative and survival outcomes were compared between the two groups.The 761 patients in this study included 113 patients who underwent bowel surgery by a GO and 648 who had bowel surgery by a GS. No discernible differences were observed in age, American Society of Anesthesiology (ASA) score, FIGO stage, histologic type, timing of cytoreductive surgery (primary or interval debulking surgery), or complications between the two groups. The GO group exhibited a shorter operation time than the GS group. Kaplan-Meier analysis showed no survival differences between the two groups. In the Cox analysis, non-serous cell types and gross residual diseases were associated with adverse effects on overall survival. However, performance of bowel surgery by a GO did not have an impact on survival.Performance of bowel surgery by a GO during maximal cytoreductive surgery is both feasible and safe. These results should be reflected in the training system for GOs regarding bowel surgery, and further research is needed to confirm that GOs can play a more leading role in performing extra-uterine procedures.© 2024. Society of Surgical Oncology.